Profits from Pfizer, BioNTech and Moderna amount to US $ 65,000 per minute due to COVID-19

According to a new analysis of the Popular Alliance for Vaccines (PVA), the companies Pfizer, BioNTech and Moderna collectively earn $ 65,000 every minute from their COVID-19 vaccines. However, in the poorest countries in the world they still do not immunize their inhabitants.

With an estimate of more than $1,000 dollars per secondAt US $ 65,000 a minute or US $ 93.5 million a day, the three companies are expected to make pre-tax profits of US $ 34 billion this year.

CAN SEE

Likewise, Pfizer announced that it expects total revenue of $ 36 billion related to the vaccine for the whole in 2021. Also, in its recent quarterly results, the immunizer against COVID-19 has had revenues of US $ 24.3 billion.

The Moderna company indicated that some doses that were to be delivered this year have been rescheduled for 2022, so it expects the sale of its vaccines to range between US $ 15,000 and US $ 18,000 million. Likewise, the company projects sales of between US $ 17,000 and US $ 22,000 million by 2022.

On the other hand, BioNTech expects revenues from the coronavirus vaccine to add up to between US $ 18,500 and US $ 19,700 million as amount for the whole year.

The PVA has questioned these revenues by companies when only the 2% of low-income countries have received the full dose of the vaccine.

CAN SEE

On the other hand, it was announced that Pfizer and BioNTech have delivered less than 1% of its total supplies to low-income countries. For its part, Moderna has only delivered 0.2%.

Likewise, PVA points out that, despite the fact that both Pfizer, BioNTech and Moderna They have received public funding of more than US $ 8 billion, they have refused to transfer vaccine technology to producers in low- and middle-income countries through the World Health Organization (WHO).

For their part, companies AstraZeneca y Johnson & Johnson They acted differently, as they have supplied their vaccines without profit, although the two companies announced that they are evaluating ending this agreement in the future and as the pandemic diminishes.

SOURCE: The Economist